BetaCurve

About Salutaris Medical Devices

SalutarisMD is pioneering a novel treatment paradigm for challenging retinal diseases with its BetaCurve device, a 510(k)-cleared platform for episcleral brachytherapy. The company is initially targeting polypoidal choroidal vasculopathy (PCV), a subtype of wet-AMD that responds poorly to standard anti-VEGF injections, with a one-time, 10-minute outpatient procedure. By leveraging precision beta radiation from a stable Strontium-90 source, BetaCurve aims to treat the root cause of the disease, potentially eliminating the need for lifelong, burdensome injections. SalutarisMD represents a compelling opportunity to address a significant unmet medical need in a large, underserved global patient population.

Therapeutic Areas